钠-葡萄糖协同转运蛋白2抑制剂与糖尿病心血管并发症研究进展

Advance in the mechanism of protective effects of SGLT-2 inhibitors on diabetic cardiovascular complications

心血管并发症是2型糖尿病(T2DM)患者致死致残的主要原因,因此心血管并发症的防治尤为关键。钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂通过增加尿糖排泄发挥独特降糖作用,为糖尿病治疗提供了一条新途径。在降糖作用以外,SGLT-2抑制剂还通过促进尿糖排泄实现能量负平衡,进而改善血糖、血脂、血压、体重水平,改善胰岛细胞功能以及胰岛素抵抗,有利于降低心血管危险因素,降低对糖尿病心血管并发症的影响,且不增加低血糖风险。

Cardiovascular complications are the leading cause of death and disability in type 2 Diabetes （T2DM） patients, so the prevention and treatment of cardiovascular complications are especially critical. Sodium-glucose cotransport 2 （SGLT-2） inhibitors provide a new approach to the treatment of diabetes by the unique hypoglycemic mechanism of increasing urinary glucose excretion. In addition to the hypoglycemic effect, SGLT-2 inhibitors can promote the excretion of urine glucose, which provide an opportunity to achieve a negative energy balance, then improve the level of blood glucose,blood pressure, weight, islet cell function and insulin resistance, and do not increase the risk of hypoglycemia and achieve cardiovascular benefits ultimately.